Target intelligence / Profile preview

Lens crystallin protein

Molecular classification
Structural protein, Molecular chaperone
01

Overview

Lens crystallin proteins are the primary structural components of the ocular lens, essential for maintaining its transparency and high refractive index (Hoenders & Bloemendal, 1983). These proteins, categorized into alpha, beta, and gamma families, are characterized by their extreme longevity and lack of turnover, making them highly susceptible to cumulative post-translational modifications over a lifetime (Balfour & Clissold, 1990). The sulfhydryl (-SH) groups of cysteine residues within these proteins are particularly vulnerable to oxidative stress, which increases as levels of the endogenous antioxidant glutathione decline with age (Babizhayev et al., 2001). Oxidation of these groups leads to the formation of inter- and intra-molecular disulfide bonds, resulting in protein cross-linking, aggregation, and the formation of light-scattering opacities known as cataracts (Truscott, 2005). Therapeutic strategies targeting these sulfhydryl groups aim to prevent or reverse this oxidative damage, either by acting as sacrificial antioxidants, stabilizing the protein structure, or reducing existing disulfide bridges to restore protein solubility (Balfour & Clissold, 1990). While pharmacological intervention remains a challenge due to the dense, avascular structure of the lens, these proteins represent a critical target for non-surgical cataract management and the preservation of visual acuity.

Other names
Sulfhydryl groups of soluble lens crystallin proteinsCrystallin thiolsLens crystallinsAlpha-crystallinBeta-crystallinGamma-crystallin
02

Mechanism of action

Prevention of oxidative modification and cross-linking of crystallin proteins by protecting or regenerating sulfhydryl groups, thereby maintaining protein solubility and lens transparency (Balfour & Clissold, 1990; Babizhayev et al., 2001).

03

Biological functions

RefractionLens transparencyProtein folding stabilization
04

Disease associations

CataractPresbyopia
05

Safety considerations

Poor bioavailability in the lens nucleus (Truscott, 2005)Potential for ocular surface irritationLack of definitive clinical evidence for cataract reversal (Balfour & Clissold, 1990)
06

Interacting drugs

Bendazac

3 more in the full profile.

07

Biomarkers

Lens opacification (LOCS III score)Glutathione concentration in aqueous humorProtein-thiol content in lens tissue

Beyond the preview

Go deeper on Lens crystallin protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lens crystallin protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call